About Manhattan Pharmaceuticals, Inc.

A development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for the treatment of both common obesity and morbid obesity. To meet the needs of other major, underserved medical markets Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for the treatment of psoriasis, and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.

About Pharma Finance 2007

A unique two-day intensive approach to find and to offer, in an international environment: AIC, Patents & Licensing, Co-Marketing of Bio-Nano-Pharma Technologies. Pharma Finance 2007 is not an arena-style conference. It is specifically designed to support in-depth partnership development.